Related Experiment Video
Updated: Dec 31, 2025
10:13
Author Spotlight: An Efficient Methodology to Confidently Differentiate and Characterize Fentanyl Analogs
Published on: November 8, 2024
2.7K
Nebulized Fentanyl for Dyspnea: A Retrospective Chart Review
Journal of Pain & Palliative Care Pharmacotherapy
|January 11, 2020
Summary
Nebulized fentanyl shows promise for treating dyspnea, with no significant side effects reported. This study suggests a potential role for nebulized fentanyl in managing shortness of breath, warranting further investigation.
Area of Science:
- Medical research
- Pharmacology
- Respiratory medicine
Background:
- Nebulized fentanyl is recognized for pain relief.
- Its efficacy and safety for treating dyspnea (shortness of breath) are not well-established.
- Further investigation is needed to explore its potential in respiratory care.
Purpose of the Study:
- To evaluate the effectiveness of nebulized fentanyl in patients experiencing dyspnea.
- To identify any adverse side effects associated with its use in this patient population.
- To assess the safety profile of nebulized fentanyl for dyspnea treatment.
Main Methods:
- Retrospective chart review of patients receiving nebulized fentanyl for dyspnea.
- Data collected from July 2014 to July 2018.
- Analysis of patient demographics, treatment outcomes, and adverse events.
Main Results:
- 360 doses administered to 73 patients (median age 67, 9-day median length of stay).
- No documented cases of bronchospasm, hypotension, or allergic reactions.
- Significant improvements observed: mean respiratory rate decreased by 4.3 breaths/min, oxygen saturation increased by 2.3%.
- 71% of patients with documented responses reported improved dyspnea.
Conclusions:
- Nebulized fentanyl appears to have a favorable safety profile for treating dyspnea.
- Preliminary findings suggest potential efficacy in improving respiratory parameters and patient-reported dyspnea.
- Further research is recommended to confirm the therapeutic role of nebulized fentanyl in dyspnea management.
Related Concept Videos
01:23Inhaled Medications
652
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
652
01:20Inhalational Anesthetics: Overview
896
Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
896
01:15Opioid Analgesics: Synthetic and Semisynthetic Opioids
838
Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...
838
01:26COPD: Management Using Bronchodilators and Corticosteroids
675
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
675
01:18Drug Delivery: Enteral Route
1.4K
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
1.4K
01:30Acute Respiratory Failure-III
683
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
683